Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.51 |
| ▸ | ITGAV | P06756 | 2/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812756 | 0.86 | DDX3X (0.80) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL1275926 | 0.84 | RAB9A (0.75) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL5852186 | 0.83 | DDX3X (0.70) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL6605242 | 0.83 | DDX3X (0.65) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL17079606 | 0.80 | RAB9A (0.66) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL3460449 | 0.80 | DDX3X (0.70) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL687547 | 0.80 | RAB9A (0.66) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL17084259 | 0.80 | RAB9A (0.67) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL751586 | 0.80 | SMN1; SMN2 (0.74) | RAB9ANPC1MAPTKMT2AHTT | |
| SCHEMBL17079634 | 0.80 | MAPT (0.61) | DDX3XRAB9ANPC1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1189881-B2 | PROPANOIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1079825-B1 | COMPOUNDS THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1567505-A4 | COMBINATION PRODUCTS WITH CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS AND OTHER THERAPEUTIC COMPOUNDS | SCHERING CORP (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20070060608-A1 | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | ENCYSIVE PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| CN-1292744-C | Carboxylic acid derivs. that inhibit binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORP (US) | 2007-01-03 | — | — | CN | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| EP-1213288-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1189881-A1 | PROPANOIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-03-27 | — | — | EP | disclosed |
| EP-1176956-A1 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-02-06 | — | — | EP | disclosed |
| CN-1311676-A | Compound that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORP (US) | 2001-09-05 | — | — | CN | disclosed |
| EP-1079825-A2 | COMPOUNDS THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000067746-A1 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000068188-A1 | PROPANOIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-11-16 | — | — | WO | disclosed |
| US-6096773-A | INHIBITOR OF BINDING OF INTEGRIN TO ITS RECEPTORS, SUCH AS (VASCULAR CELL ADHESION MOLECULE-1) AND FIBRONECTIN AND USEFUL FOR CONTROLLING THE DISEASES INDUCED BY BINDING | TEXAS BIOTECHNOLOGY CORPORATION, INC. (US) | 2000-08-01 | — | — | US | disclosed |
| WO-1999052493-A2 | COMPOUNDS THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | DDX3X 4863/4885RAB9A 2399/4885NPC1 1929/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | DDX3X 3795/4885RAB9A 2372/4885NPC1 564/4885 |
| US-20070060608-A1 | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | VCAM1, ITGB1, ICAM1 | DDX3X 4840/4885RAB9A 2385/4885NPC1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.